Selecting appropriate therapy for lower-risk myelodysplastic syndromes: current state and future prospects

Expert Opin Pharmacother. 2024 Oct;25(15):1975-1977. doi: 10.1080/14656566.2024.2415714. Epub 2024 Oct 16.

Authors

Farzad Teymouri¹, Constantin A Dasanu^{2

3}

Affiliations

¹ Department of Medicine, Eisenhower Health, Rancho Mirage, CA, USA.
² Lucy Curci Cancer Center, Eisenhower Health, Rancho Mirage, CA, USA.
³ Department of Medical Oncology and Hematology, UC San Diego Health System, San Diego, CA, USA.

PMID: 39387446
DOI: 10.1080/14656566.2024.2415714

No abstract available

Keywords: Myelodysplastic syndrome; genetic alterations in MDS; lower-risk myelodysplastic syndromes (LR-MDS); therapeutic strategies in MDS.

Publication types

Editorial